Brinton Pharmaceuticals Appoints Sathya Narayanan as CEO for India Cluster & JPAC

He previously served as MD of Galderma South Asia/Emcutix, leading business expansion efforts and strengthening the company’s presence in the dermatology market.

Brinton Pharmaceuticals, a Pune-based pharma company, has appointed Sathya Narayanan as Chief Executive Officer for the India Cluster and Japan Asia Pacific (JPAC) region, as the company sharpens its expansion strategy across India and neighbouring healthcare markets.

The appointment comes as Brinton continues to scale its dermatology and speciality therapies portfolio globally.

Narayanan joins Brinton Pharmaceuticals with more than two decades of leadership experience spanning pharmaceuticals and dermatology. He previously served as Managing Director of Galderma South Asia/Emcutix, where he led business expansion efforts and helped strengthen the company’s presence in the region’s dermatology market.

Commenting on the appointment, Rahulkumar Darda, Chairman & Managing Director, Brinton Pharmaceuticals, said, “Sathya’s experience in scaling organizations and creating high-impact healthcare ecosystems will play a pivotal role in further strengthening Brinton’s leadership across India and the JPAC region. Brinton continues to expand its footprint across 62 countries, while further strengthening its presence in the USA, Europe, and other strategic global markets.”

Narayanan has also held leadership positions within industry bodies, including serving on the Executive Committee of the Organization of Pharmaceutical Producers of India (OPPI), where he contributed to initiatives related to medical affairs, regulatory strategy, and legal frameworks in healthcare.

Narayanan said, “Brands such as UV Doux, which has emerged as one of India’s leading dermatologist-prescribed sunscreen brands, reflect Brinton’s ability to create science-backed healthcare solutions with growing acceptance across India as well as global markets.”

Brinton Pharmaceuticals currently operates across 62 countries and continues to invest in research and development, next-generation formulations, and speciality healthcare products.

Stay tuned for more such updates on Digital Health News